Clinical Trials Logo

Glioblastoma clinical trials

View clinical trials related to Glioblastoma.

Filter by:

NCT ID: NCT00458601 Completed - Malignant Glioma Clinical Trials

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

ACT III
Start date: August 2007
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose.

NCT ID: NCT00445588 Completed - Adult Glioblastoma Clinical Trials

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving erlotinib together with sorafenib works in treating patients with progressive or recurrent glioblastoma multiforme. Erlotinib and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving erlotinib together with sorafenib may kill more tumor cells.

NCT ID: NCT00441142 Completed - Clinical trials for Glioblastoma Multiforme

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

Zactima
Start date: May 25, 2007
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I: The purpose of this research study is to determine the safety of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment of glioblastomas. We will determine the highest dose of ZD6474 (Vandetanib) that can be given safely when combined with temozolomide (Temodar) and radiation therapy. Phase II: The purpose of this research study is to determine the efficacy of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment of glioblastomas. All subjects participating in this research study must NOT be taking a certain type of anti-seizure medication called enzyme inducing anticonvulsant drugs. These drugs include (but are not limited to) the following medications: Dilantin, Tegretol, Phenobarbital and trileptal.

NCT ID: NCT00436436 Completed - Clinical trials for Brain and Central Nervous System Tumors

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Start date: December 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as O(6)-benzylguanine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving O(6)-benzylguanine together with temozolomide works in treating patients with glioblastoma multiforme that did not respond to previous temozolomide and radiation therapy.

NCT ID: NCT00433381 Completed - Adult Glioblastoma Clinical Trials

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Start date: March 1, 2007
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with irinotecan or temozolomide may kill more tumor cells.

NCT ID: NCT00431561 Completed - Glioblastoma Clinical Trials

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade glioma.

NCT ID: NCT00430911 Completed - Clinical trials for Glioblastoma Multiforme

Radiotherapy for Malignant Astrocytomas in the Elderly

Start date: February 2001
Phase: Phase 3
Study type: Interventional

A randomized trial comparing radiotherapy with supportive care in patients aged 70 years or older with newly diagnosed, histologically confirmed anaplastic astrocytoma or glioblastoma, and a Karnofsky performance status > 70.

NCT ID: NCT00424060 Completed - Clinical trials for Brain and Central Nervous System Tumors

Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma

Start date: December 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as epothilone ZK-219477, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone ZK-219477 works in treating patients with recurrent glioblastoma.

NCT ID: NCT00423735 Completed - Adult Glioblastoma Clinical Trials

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Start date: January 24, 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00412542 Completed - Glioma Clinical Trials

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

Start date: October 2003
Phase: Phase 2
Study type: Interventional

Objectives: 1.1 To determine the efficacy, as measured by 6 month progression-free survival, of therapy with thalidomide combined with CPT-11 in the treatment of patients with recurrent and/or progressive malignant gliomas. 1.2 To determine the rate of measureable clinical response in patients treated with Thalidomide and CPT-11. 1.3 To determine Thrombotic thrombocytopenic purpura (TTP), overall survival and unexpected toxicity of Thalidomide and CPT-11 used in recurrent malignant gliomas. 1.4 To determine changes in dynamic magnetic resonance imaging (MRI) as a surrogate marker for treatment effect.